Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β-amyloid accumulation

被引:29
作者
Laitinen, KSM
van Groen, T
Tanila, H
Venäläinen, J
Männistö, PT
Alafuzoff, I
机构
[1] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland
[3] Kuopio Univ Hosp, Dept Pathol, SF-70210 Kuopio, Finland
关键词
Alzheimer's disease; beta-amyloid; neurofibrillary degeneration; prolyl oligopeptidase; transgenic mice;
D O I
10.1097/00001756-200110290-00032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Prolyl oligopeptidase (POP) have been suggested to participate in the pathogenesis of Alzheimer's disease (AD). In this study the activity of POP is evaluated in AD patients and in transgenic mice with substantial deposits of beta -amyloid (A beta). In AD cases, the POP activity displayed a significant negative correlation with the scores of senile/neuritic plaques and neurofibrillary tangles but not with A beta -load. The transgenic mice with high levels of A beta did not have altered POP activity compared to wild type mice. Based on our results, the low POP activity in AD seems to be associated with neuronal degeneration rather than to A beta accumulation. NeuroReport 12:3309-3312 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:3309 / 3312
页数:4
相关论文
共 20 条
[11]   Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease [J].
Mantle, D ;
Falkous, G ;
Ishiura, S ;
Blanchard, PJ ;
Perry, EK .
CLINICA CHIMICA ACTA, 1996, 249 (1-2) :129-139
[12]   THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .2. STANDARDIZATION OF THE NEUROPATHOLOGIC ASSESSMENT OF ALZHEIMERS-DISEASE [J].
MIRRA, SS ;
HEYMAN, A ;
MCKEEL, D ;
SUMI, SM ;
CRAIN, BJ ;
BROWNLEE, LM ;
VOGEL, FS ;
HUGHES, JP ;
VANBELLE, G ;
BERG, L .
NEUROLOGY, 1991, 41 (04) :479-486
[13]  
MOLSA PK, 1987, ACTA NEUROL SCAND, V75, P376
[14]   Novel proline endopeptidase inhibitors do not modify Aβ40/42 formation and degradation by human cells expressing wild-type and Swedish mutated β-amyloid precursor protein [J].
Petit, A ;
Barelli, H ;
Morain, P ;
Checler, F .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (07) :1613-1617
[15]   DECREASED PROLINE ENDOPEPTIDASE ACTIVITY IN THE BASAL GANGLIA IN HUNTINGTONS-DISEASE [J].
PITTAWAY, KM ;
REYNOLDS, GP ;
EMSON, PC .
JOURNAL OF NEUROCHEMISTRY, 1984, 43 (03) :878-880
[16]   Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells [J].
Shinoda, M ;
Toide, K ;
Ohsawa, I ;
Kohsaka, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) :641-645
[17]   Affected enzyme activities in Alzheimer's disease are sensitive to antemortem hypoxia [J].
Terwel, D ;
Bothmer, J ;
Wolf, E ;
Meng, FP ;
Jolles, J .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 161 (01) :47-56
[18]  
TOIDE K, 1995, J PHARMACOL EXP THER, V274, P1370
[19]   Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain [J].
Toide, K ;
Fujiwara, T ;
Iwamoto, Y ;
Shinoda, M ;
Okamiya, K ;
Kato, T .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 353 (03) :355-362
[20]   PROLYL ENDOPEPTIDASE [J].
WILK, S .
LIFE SCIENCES, 1983, 33 (22) :2149-2157